Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | PRKDC | P78527 | 3/20 | 0.36 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11482703 | 0.82 | PAX8 (0.39) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL10967544 | 0.73 | CA12 (0.41) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL4202579 | 0.72 | CYP1A2 (0.35) | PARP1PRKDCALDH1A1HPGDHSD17B10 | |
| SCHEMBL5658467 | 0.67 | PRKDC (0.42) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL29672392 | 0.67 | PRKDC (0.42) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL6330126 | 0.66 | MCL1 (0.46) | ALDH1A1CYP1A2TSHRMEN1KMT2A | |
| SCHEMBL3344842 | 0.65 | BRD4 (0.33) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL530252 | 0.65 | HTR1A (0.36) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL11398596 | 0.65 | HTR1A (0.36) | CA12CA9BRD4BRPF1KAT2B | |
| SCHEMBL7004592 | 0.65 | PARP1 (0.44) | PARP1PRKDCHSD17B10PTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384154-A | Pyrroloquinolinone compound, synthesis method and application thereof | 广州医科大学 | 2024-01-12 | — | — | CN | disclosed |
| US-20230089412-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-11559540-B2 | Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-24 | — | — | US | disclosed |
| US-20220143006-A1 | METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3995589-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | Kura Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114306604-A | Use of farnesyl transferase inhibitors for the treatment of cancer | 库拉肿瘤学公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110325212-B | Farnesyl transferase inhibitors for use in methods of treating cancer | 库拉肿瘤学公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114107497-A | Use of farnesyl transferase inhibitors for the treatment of cancer | 库拉肿瘤学公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-2136807-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| EP-2041145-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008003690-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1173440-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064899-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-02 | — | — | WO | disclosed |